aflitzy

Four Biotech Stocks to Play the Sector Pullback

CEL-SCI's L.E.A.P.S.(TM) H1N1 Flu Development Seen as Credibility Booster
12:34 pm ET 11/06/2009- Business Wire
LOS ANGELES--(BUSINESS WIRE)--

BioMedReports.com, the news portal which covers Wall Street's biomedical

sector and delivers financial and investment intelligence to a community

of highly informed investors, reports that one of several expected key

news developments has been announced by CEL-SCI Corporation (NYSE Amex:

CVM), today.


An Institutional Review Board of The Johns Hopkins University School of

Medicine (Johns Hopkins) has given clearance for the Company's first

clinical study involving the much talked about L.E.A.P.S.(TM) H1N1

investigational therapy.


The initiation of CEL-SCI's rapidly-accelerated LEAPS-H1N1 clinical

development program builds on CEL-SCI's pioneering work with its

L.E.A.P.S.(TM) technology, whose reach goes beyond the H1N1 space, and

whose responses can be designed to be directed at a great number of

human diseases.


Investors, who have sent the stock price up on the news, apparently also

view the news as a much needed credibility boost in light of recent

attacks by a single columnist against the company. Despite those

published attacks, shares of the company have risen dramatically in the

past few months and many expect that trend to continue as the company

moves forward on several fronts, including a pending, and long

anticipated launch of Phase III trials for Multikine(R), CEL-SCI's

flagship cancer immunotherapeutic agent, which is being developed as a

first-line standard of care cancer treatment.


The complete report is available now at BioMedReports.com:


biomedreports.com/arti...

BioDelivery Sciences Requires Strong Investor Confidence

Gino, thank you for your comments - very informative.
Question:
Do you know why Elliott tried to remove management 2 years ago???
This may sound really dumb, but seems like very bad timing for Elliott to sell BDSI unless they had a short postion they needed to unwind prior to approval. Or were they convinced of non approval and wanted to get out fast.

Thanks


On Sep 30 11:53 AM gino wrote:

> I don't agree with your reasons why BDSI stock traded down. Elliott
> associates, a $10B NY hedge fund, started selling out their entire
> position on June15th. They sold close to 1.5M shares through various
> funds before the FDA gave it decision. When the FDA approved the
> drug and spiked up to $7.25 they sold off the rest of their entire
> position over the following few weeks. They filed with the SEC that
> they do not own any more shares of the stock but they do still own
> 1.9M warrants. If you google BDSI along with Elliott you will see
> they tried to remove the management of BDSI two years ago and were
> not successful. I have to believe there was some disagreements between
> them and BDSI. Either way, IF they did not sell out of their position
> and were still long BDSI stock could have been north of $10.00 right
> now. I think they broke the stock down and scared everyone out. The
> reality is they GOT the approval which validates the BEMA technology
> and sets them up for sucess with future BEMA products. I think this
> is one of the most undervalued pharmaceuticals companies on the street.
> When the rest of wall street wakes up to what really drove the stock
> down and recognizes the opportunity it will be already to late.